SGN CD30C
Alternative Names: PF-08046045; SGN-35T; SGN-CD30CLatest Information Update: 25 Mar 2025
At a glance
- Originator Seattle Genetics
- Developer Seagen
- Class Antibodies; Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Immunotherapies; Immunotoxins
- Mechanism of Action DNA topoisomerase I inhibitors; Hypoxia-inducible factor 1 alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Lymphoma; Solid tumours
Most Recent Events
- 12 Feb 2024 Phase-I clinical trials in Solid tumours (Late-stage disease) (Parenteral), prior to February 2024 (Pfizer pipeline, February 2024)
- 02 Jan 2024 Phase-I clinical trials in Lymphoma (Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT06120504)
- 14 Dec 2023 Seagen has been acquired by Pfizer